CG Oncology, Inc. Common stock (CGON) — Technical state
As of 2026-10-30 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 42 out of 100 (momentum 52 · quality 3 · valuation 6), as of 2026-11-01.
- Signal: Mixed moving-average stack — Trades -6.8% vs the 50-day and -1.9% vs the 200-day average, 20.1% below the 52-week high and +80.7% off the 52-week low. Computed from daily closes. (as of 2026-10-30)
- Trend: CG Oncology, Inc. Common stock trades 6.8% below its 50-day and 1.9% below its 200-day moving average. (as of 2026-10-30)
CG Oncology develops cretostimogene, an experimental virus-based immunotherapy that trains the immune system to attack bladder tumours after standard BCG treatment fails. The company runs several late-stage trials testing the therapy alone in different bladder-cancer stages, from high-risk disease to intermediate-risk cases after surgery.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the CGON overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades -6.8% vs the 50-day and -1.9% vs the 200-day average, 20.1% below the 52-week high and +80.7% off the 52-week low. Computed from daily closes.
The moving-average stack
- vs 20-day+3%
- vs 50-day-6.8%
- vs 200-day-1.9%
- 52-week band20.1% off the high · +80.7% off the low
- Streak1 consecutive up session
- 50-day crossprice crossed down through the 50-day 27 sessions ago
- Stochastic%K 83.7 · %D 69
Continue: the CGON chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-10-30
Quick answers
What is the current Closelooknet signal on CGON?
Mixed moving-average stack — Trades -6.8% vs the 50-day and -1.9% vs the 200-day average, 20.1% below the 52-week high and +80.7% off the 52-week low. Computed from daily closes. As of 2026-10-30; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is CGON above its 50-day and 200-day moving averages?
As of 2026-10-30, CG Oncology, Inc. Common stock trades -6.8% below its 50-day and -1.9% below its 200-day average, with the 20-day +3% away.
How far is CGON from its 52-week high?
20.1% below the 52-week high and 80.7% above the 52-week low, as of 2026-10-30.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- HALO Halozyme Therapeutics Incindustry
- ONC BeiGene, Ltd.industry
- UCB.BR UCB SAindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- KOD Kodiak Sciences Incindustry
- REPL Replimune Group Incindustry
- MRNA Moderna Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- DNA Ginkgo Bioworks Holdingsindustry
- ABSI Absci Corpindustry
- EXEL Exelixis Incindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- XNCR Xencor Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- ADMA ADMA Biologics Incindustry
- VRDN Viridian Therapeutics Incindustry
- IRON Disc Medicine Inc.industry
- BHVN Biohaven Ltd.industry